{"id":837911,"date":"2025-04-16T07:34:03","date_gmt":"2025-04-16T11:34:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\/"},"modified":"2025-04-16T07:34:03","modified_gmt":"2025-04-16T11:34:03","slug":"lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\/","title":{"rendered":"LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation"},"content":{"rendered":"
\n

\n Exemption from the $5.1 million repayment obligation strengthens LAVA\u2019s balance sheet<\/em>\n <\/p>\n

\n Underscores focus on cost curtailment and strategic option evaluation<\/em>\n <\/p>\n

UTRECHT, The Netherlands and PHILADELPHIA, April 16, 2025 (GLOBE NEWSWIRE) — LAVA<\/u>Therapeutics<\/u>N.V.<\/u><\/a>\u00a0(NASDAQ: LVTX, \u201cLAVA,\u201d \u201cthe Company\u201d), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody\u00ae<\/sup> platform of bispecific gamma delta T cell engagers, today announced that the Netherlands Enterprise Agency (Rijksdienst voor Ondernemend Nederland, RVO) granted a full waiver of the final payment obligation related to the Innovation Credit, in the amount of $5.1 million.<\/p>\n

\u201cAs part of LAVA\u2019s ongoing strategic review, we have implemented a targeted cost optimization initiative to enhance operational efficiency and financial flexibility,\u201d said Steve Hurly, Chief Executive Officer of LAVA. \u201cSecuring the $5.1 million repayment waiver is a significant milestone in this effort. This waiver strengthens our balance sheet by eliminating this outstanding debt obligation. We are grateful for the opportunity to work with the RVO and be part of the Innovation Credit program.\u201d<\/p>\n

The Netherlands Enterprise Agency (Rijksdienst voor Ondernemend Nederland, RVO) Innovation Credit provides financing in the form of an interest-bearing loan to support the development of innovative programs according to defined criteria. LAVA was awarded a Netherlands Innovation Credit in 2019 related to the development of LAVA-051 and pledged certain assets of that project, including certain intellectual property (IP), as a guarantee.<\/p>\n

\n About LAVA Therapeutics <\/strong>\n <\/p>\n

LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on advancing its proprietary Gammabody\u00ae<\/sup> platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid tumors and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering V\u03b39V\u03b42 (Vgamma9 Vdelta2) T cell anti-tumor effector functions upon cross-linking to tumor-associated antigens.<\/p>\n

LAVA\u2019s pipeline includes three internal and partnered clinical-stage bispecific gamma-delta T cell engagers for the treatment of solid tumor and hematological cancers including LAVA 1266, targeting CD123+ cancers (ACTRN12624001214527); PF-08046052, targeting EGFR (NCT05983133); and JNJ-89853413, targeting hematological cancers (NCT06618001). The pipeline also includes preclinical programs. For more information on LAVA, please visit our website at www.lavatherapeutics.com<\/a> or follow us on\u00a0LinkedIn<\/u><\/a>,\u00a0X<\/u><\/a>, and\u00a0YouTube<\/u><\/a>.<\/p>\n

Gammabody\u00ae<\/sup> is a registered trademark of LAVA Therapeutics N.V.<\/p>\n

\n LAVA\u2019s<\/strong>
\n Cautionary<\/strong>
\n Note<\/strong>
\n on<\/strong>
\n Forward-Looking<\/strong>
\n Statements <\/strong>\n <\/p>\n

\n This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are \u201cforward-looking statements\u201d. Words such as \u201canticipate\u201d, \u201cbelieve\u201d, \u201ccould\u201d, \u201cwill\u201d, \u201cmay\u201d, \u201cexpect\u201d, \u201cshould\u201d, \u201cplan\u201d, \u201cintend\u201d, \u201cestimate\u201d, \u201cpotential\u201d, \u201csuggests\u201d, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on LAVA\u2019s expectations and assumptions as of the date of this press release and are subject to various risks and uncertainties that may cause actual results to differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements relating to LAVA\u2019s initiatives to increase cost optimization and efficiencies. Many factors, risks and uncertainties may cause differences between current expectations and actual results, including, among other things, LAVA\u2019s ability to leverage its initial programs to develop additional product candidates using its Gammabody\u00ae platform, the failure of LAVA\u2019s collaborators to support or advance collaborations or LAVA\u2019s product candidates, the timing and results of LAVA\u2019s research and development programs and preclinical and clinical trials, the possibility that clinical trials may fail to establish sufficient efficacy, the risk that adverse events or safety signals may occur in clinical trials, the risk that results obtained in preclinical studies or clinical trials to date may not be indicative of results obtained in ongoing or future trials, the risk that adverse regulatory actions or other setbacks could occur in clinical trials even after promising results in earlier clinical trials or preclinical studies, LAVA\u2019s ability to obtain regulatory approval for and commercialize its product candidates, LAVA\u2019s ability to identify any strategic alternatives or if so identified, be able to consummate any such transactions on terms acceptable to LAVA and its shareholders, and the risk that setbacks in development could occur as a result of the difficulty and uncertainty of pharmaceutical product development and other factors. There may be adverse effects on LAVA\u2019s business condition and results from general economic and market conditions and overall fluctuations in the United States and international credit and financial markets, including as a result of inflation, heightened interest rates, recent and potential future pandemics and other health crises, and hostilities, including the conflict in Ukraine and the conflict in the Middle East. These and other risks are described in greater detail under the caption \u201cRisk Factors\u201d in LAVA\u2019s most recent Annual Report on Form 10-K and other filings LAVA makes with the U.S. Securities and Exchange Commission. LAVA assumes no obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, change in expectations or otherwise, except as otherwise required by law.<\/em>\n <\/p>\n

\n
\n CONTACTS<\/u>
\n <\/strong>
\n
Investor Relations
ir@lavatherapeutics.com<\/u><\/a><\/p>\n

LifeSci Advisors (IR\/Media)
Joyce Allaire
Jallaire@lifesciadvisors.com<\/u><\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Exemption from the $5.1 million repayment obligation strengthens LAVA\u2019s balance sheet Underscores focus on cost curtailment and strategic option evaluation UTRECHT, The Netherlands and PHILADELPHIA, April 16, 2025 (GLOBE NEWSWIRE) — LAVATherapeuticsN.V.\u00a0(NASDAQ: LVTX, \u201cLAVA,\u201d \u201cthe Company\u201d), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody\u00ae platform of bispecific gamma delta T cell engagers, today announced that the Netherlands Enterprise Agency (Rijksdienst voor Ondernemend Nederland, RVO) granted a full waiver of the final payment obligation related to the Innovation Credit, in the amount of $5.1 million. \u201cAs part of LAVA\u2019s ongoing strategic review, we have implemented a targeted cost optimization initiative to enhance operational efficiency and financial flexibility,\u201d said Steve Hurly, Chief Executive Officer of LAVA. \u201cSecuring the $5.1 million … <\/p>\n

Continue reading “LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-837911","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLAVA Therapeutics Granted Full Waiver for RVO Payment Obligation - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Exemption from the $5.1 million repayment obligation strengthens LAVA\u2019s balance sheet Underscores focus on cost curtailment and strategic option evaluation UTRECHT, The Netherlands and PHILADELPHIA, April 16, 2025 (GLOBE NEWSWIRE) — LAVATherapeuticsN.V.\u00a0(NASDAQ: LVTX, \u201cLAVA,\u201d \u201cthe Company\u201d), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody\u00ae platform of bispecific gamma delta T cell engagers, today announced that the Netherlands Enterprise Agency (Rijksdienst voor Ondernemend Nederland, RVO) granted a full waiver of the final payment obligation related to the Innovation Credit, in the amount of $5.1 million. \u201cAs part of LAVA\u2019s ongoing strategic review, we have implemented a targeted cost optimization initiative to enhance operational efficiency and financial flexibility,\u201d said Steve Hurly, Chief Executive Officer of LAVA. \u201cSecuring the $5.1 million … Continue reading "LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-16T11:34:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMzA1NSM2ODY4NTk5IzIyMDY3OTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation\",\"datePublished\":\"2025-04-16T11:34:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\\\/\"},\"wordCount\":864,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMzA1NSM2ODY4NTk5IzIyMDY3OTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\\\/\",\"name\":\"LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMzA1NSM2ODY4NTk5IzIyMDY3OTE=\",\"datePublished\":\"2025-04-16T11:34:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMzA1NSM2ODY4NTk5IzIyMDY3OTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMzA1NSM2ODY4NTk5IzIyMDY3OTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\/","og_locale":"en_US","og_type":"article","og_title":"LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation - Market Newsdesk","og_description":"Exemption from the $5.1 million repayment obligation strengthens LAVA\u2019s balance sheet Underscores focus on cost curtailment and strategic option evaluation UTRECHT, The Netherlands and PHILADELPHIA, April 16, 2025 (GLOBE NEWSWIRE) — LAVATherapeuticsN.V.\u00a0(NASDAQ: LVTX, \u201cLAVA,\u201d \u201cthe Company\u201d), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody\u00ae platform of bispecific gamma delta T cell engagers, today announced that the Netherlands Enterprise Agency (Rijksdienst voor Ondernemend Nederland, RVO) granted a full waiver of the final payment obligation related to the Innovation Credit, in the amount of $5.1 million. \u201cAs part of LAVA\u2019s ongoing strategic review, we have implemented a targeted cost optimization initiative to enhance operational efficiency and financial flexibility,\u201d said Steve Hurly, Chief Executive Officer of LAVA. \u201cSecuring the $5.1 million … Continue reading \"LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-16T11:34:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMzA1NSM2ODY4NTk5IzIyMDY3OTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation","datePublished":"2025-04-16T11:34:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\/"},"wordCount":864,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMzA1NSM2ODY4NTk5IzIyMDY3OTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\/","name":"LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMzA1NSM2ODY4NTk5IzIyMDY3OTE=","datePublished":"2025-04-16T11:34:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMzA1NSM2ODY4NTk5IzIyMDY3OTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMzA1NSM2ODY4NTk5IzIyMDY3OTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-granted-full-waiver-for-rvo-payment-obligation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/837911","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=837911"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/837911\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=837911"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=837911"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=837911"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}